Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder

Trial Profile

Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Dysthymic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2012 Additional lead trial investigator (David J. Hellerstein) identified as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 05 Jun 2007 Status changed from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top